Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain

Carlos Crespo (), Estela Moreno (), Jordi Sierra (), Suzan Serip () and Marta Rubio ()

Health Economics Review, 2013, vol. 3, issue 1, 1-10

Abstract: The analysis showed that the use of azacitidine in the treatment of high-risk myelodysplastic syndrome is a cost-effective option compared with conventional care regimen options used in the Spanish setting and had an incremental cost-effectiveness ratio within the range of the thresholds accepted by health authorities. Copyright Crespo et al.; licensee Springer. 2013

Keywords: Cost-effectiveness; Myelodysplastic syndrome; Azacitidine; Chemotherapy; Best supportive care (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1186/2191-1991-3-28 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:3:y:2013:i:1:p:1-10:10.1186/2191-1991-3-28

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/2191-1991-3-28

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().